

P/3610-57

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Jean-Pierre VORS et al.

Date: December 9, 2008

Serial No.: 10/532,033

Group Art Unit: 1614

Filed: August 9, 2005

Examiner: Zarek, P. E.

For:

ANTIFUNGAL MEDICAMENTS COMPRISING ARYLAMIDINE DERIVATIVES

## **TERMINAL DISCLAIMER**

Mail Stop Amendment Commissioner of Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

This terminal disclaimer is submitted under Rule 321 (c) to obviate a non-statutory double-patenting rejection over a co-pending application, which is being filed in response to an office action of September 10, 2008, in reference to the above-identified patent application.

Application Numbers 10/489,151 and 10/589,011 are assigned to BAYER CROPSCIENCE S.A., 16 Jean-Marie Leclair, F-69009, Lyon, France. BAYER CROPSCIENCE S.A. thus holds a 100 percent interest in the above-identified application and Application Nos. 10/489,151 and 10/589,011 and disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term, defined in 35 U.S.C. §§ 154, 156, and 173 as shortened by any terminal disclaimer filed prior to the grant, of any patent or patents granted on said Application Nos.

10/489,151 and 10/589,011. The owner agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent or patents granted on said Application Nos. 10/489,151 and 10/589,011 are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors, or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term, as defined in 35 U.S.C. §§ 145 to 156 and 173, of any patent or patents granted on said Application Nos. 10/489,151 and 10/589,011, as shortened by any terminal disclaimer filed prior to its patent grant, in the event that such patent(s): (1) expire(s) for failure to pay a maintenance fee, (2) is (are) held unenforceable, (3) is (are) found invalid by a court of competent jurisdiction, (4) is (are) statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §§ 1.321, (5) has (have) all claims cancelled by a re-examination certificate, (6) is (are) reissued, or (7) is (are) in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its (their) grant.

For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further, that these statements were made with the knowledge that willful false statements and the like so made are

Appl. No. 10/532,033 TERMINAL DISCLAIMER dated December 9, 2008 Response to Office Action of September 10, 2008



punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that any such willful false statement may jeopardize the validity of the application or any patent issued thereon.

The fee of \$140 for a terminal disclaimer under 37 C.F.R. § 1.20(d) is requested to be charged to Deposit Account No. 15-0700.

Respectfully submitted,

Paul Grandinetti

Reg. No. 30,754

OSTROLENK, FABER, GERB & SOFFEN, LLP

1180 Avenue of the Americas

New York, New York 10036-8403

Telephone (202) 457-7785

Appl. No. 10/532,033
TERMINAL DISCLAIMER dated December 9, 2008
Response to Office Action of September 10, 2008



punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that any such willful false statement may jeopardize the validity of the application or any patent issued thereon.

The fee of \$140 for a terminal disclaimer under 37 C.F.R. § 1.20(d) is requested to be charged to Deposit Account No. 15-0700.

Respectfully submitted,

Paul Grandinetti

Reg. No. 30,754

OSTROLENK, FABER, GERB & SOFFEN, LLP

1180 Avenue of the Americas

New York, New York 10036-8403

Telephone (202) 457-7785

